ClinicalTrials.gg
Status unknownNCT05360368Updated May 5, 2022

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HLX07 in Solid Tumor, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer to participate in this clinical study; completely understand and know this study as well as sign the form (ICF);
  • Aged ≥ 18 years, ≤ 75 years;
  • Patients must have confirmed malignant solid tumors which are advanced or , have failed prior standard treatment, and be intolerant or ineligible for standard therapy;
  • according to Version 1.1;
  • (ECOG) performance status 0 or 1;
  • Expected survival 12 weeks;
  • Adequate organ function;
  • For fertile female subjects, the pregnancy test must be negative within 7 days before the first dose;

Exclusion criteria

Exclusion Criteria:

  • Prior anti-EGFR (including EGFR ADC) monoclonal antibody therapy;
  • A history of other within two years, except for cured Localized tumor;
  • Participants with any prior allogeneic solid organ or bone marrow transplantations;
  • Symptomatic brain or meningeal (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable);
  • Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage;
  • Active clinical severe infection;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    HLX07

    This study uses the "3+3" design to investigate the safety and determine the MTD of HLX07. Four dose levels of 800 mg, 1200 mg, 1500 mg and 1800 mg are planned for dose finding. Enrollment will continue until a maximum of 24 patients are enrolled.

    Drug: HLX07

Interventions

  • DrugHLX07

    A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle

    Also known as: Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection

06

What researchers measure

Primary outcomes

  1. The Incidence of Treatment-Related Adverse Events

    Time frame: 2 years

  2. The proportion of patients experiencing dose limiting toxicity (DLT) events

    Time frame: from first dose to the end of Cycle 1 (each cycle is 21 days)

  3. The maximum tolerated dose (MTD)

    Time frame: from first dose to the end of Cycle 1 (each cycle is 21 days)

Secondary outcomes

  1. Peak plasma concentration (Cmax) of HLX07

    Time frame: 2 years

  2. Time to peak (Tmax) of HLX07

    Time frame: 2 years

  3. Area under the concentration-time curve (AUC) of HLX07

    Time frame: 2 years

  4. Elimination half-life (t1/2) of HLX07

    Time frame: 2 years

  5. Clearance (CL) of HLX07

    Time frame: 2 years

  6. Volume of distribution (Vz) of HLX07

    Time frame: 2 years

  7. Accumulation Index (Rac) of HLX07

    Time frame: 2 years

  8. Incidence of treatment-emergent anti-drug antibodies (ADA)

    Time frame: 2 years

  9. Objective response rate (ORR)

    Time frame: 2 years

  10. Disease control rate (DCR)

    Time frame: 2 years

  11. Duration of response (DOR)

    Time frame: 2 years

07

Study locations

1 site
  • Fudan University shanghai cancer center
    Shanghai, 200000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for Dec 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 4, 2022
StartEst.
Mar 30, 2023
Primary completionEst.
Dec 30, 2023
CompletionEst.
Feb 28, 2024
Last update
May 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05360368
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Mar 30, 2023 (estimated)
Primary completion
Dec 30, 2023 (estimated)
Completion
Feb 28, 2024 (estimated)
Last update
May 5, 2022

Study contacts

Xuhui Hu, MD
Contact
Xuhui_Hu@henlius.com
18618313742

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX07

Start the discussion